LG Chem has launched 'UtiPro Injection 25mg' in South Korea, a progesterone subcutaneous injection for luteal phase support in assisted reproductive technology (ART). This move strengthens the company's fertility and women's health portfolio, offering a locally managed alternative to imported products and addressing supply stability concerns for overseas buyers sourcing reproductive health pharmaceuticals.
Product details and regulatory approval
UtiPro is a self-administered progesterone subcutaneous injection approved for luteal phase support in infertile women undergoing ART who cannot use or tolerate vaginal formulations. Progesterone plays a critical role in preparing the uterine lining for embryo implantation and maintaining early pregnancy. The product targets the growing demand for assisted reproduction medicines driven by rising marriage and childbirth ages.
Supply-chain implications
Previously, the subcutaneous progesterone market in South Korea relied heavily on single imported products, creating potential supply risks. By launching UtiPro, LG Chem aims to directly manage quality and supply, reducing dependency on foreign sources. This development signals a shift toward localized production of key fertility drugs, which may interest global distributors and formulators seeking alternative supply chains.
Portfolio expansion strategy
LG Chem already supplies a range of fertility products in South Korea, including ovulation inducers (Follitropin, IVF-M HP, Ganirelix) and egg/embryo cryopreservation items. In 2023, the company launched 'Bloom,' a mobile app supporting pregnancy preparation and fertility treatment, which won the Smart App Award. This digital tool complements its pharmaceutical offerings, enhancing patient engagement.
What buyers should watch
In March 2024, LG Chem signed an exclusive distribution agreement with Mochida Pharmaceutical for 'Dinagest' (dienogest), an oral progestin for endometriosis, covering South Korea and Thailand. Dinagest holds over 80% market share in Japan. This expansion from fertility into broader women's health indicates LG Chem's ambition to become a comprehensive supplier in the region, potentially opening new sourcing opportunities for overseas buyers.
China sourcing context
While LG Chem's current focus is on South Korea and select Asian markets, its growing portfolio in fertility and women's health may influence regional supply dynamics. Importers and distributors in China and Southeast Asia should monitor LG Chem's regulatory filings and partnership developments, as the company could emerge as a competitive supplier of progesterone-based therapies and endometriosis treatments.
Source: Read the original report | Published: May 08, 2026